US3655899A - N-trityl-imidazoles for treating fungal infections - Google Patents

N-trityl-imidazoles for treating fungal infections Download PDF

Info

Publication number
US3655899A
US3655899A US36425A US3655899DA US3655899A US 3655899 A US3655899 A US 3655899A US 36425 A US36425 A US 36425A US 3655899D A US3655899D A US 3655899DA US 3655899 A US3655899 A US 3655899A
Authority
US
United States
Prior art keywords
imidazole
methyl
diphenyl
trityl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US36425A
Inventor
Karl H Buchel
Erik Regel
Manfred Plempel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of US3655899A publication Critical patent/US3655899A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Definitions

  • R, R and R are hydrogen, lower alkyl or phenyl, or R and R together form an anellated benzene ring,
  • X, X and X" are alkyl of 1 to 12 carbon atoms or an electro-negative moiety
  • n, n and n are an integer from 0 to 2
  • the present invention is concerned with N-tritylimidazoles and salts thereof and the production of such compounds. More particularly, the present invention is concerned with N-trityl-imidazoles and sales thereof of the formula:
  • R, R and R are hydrogen, lower alkyl or phenyl, or R and R together from an anellated benzene ring, X, X and X are alkyl of 1 to 12 carbon atoms or an electro-negative moiety, and n, n" and n" are an integer from 0 to 2,
  • alkyl moieties those having 1 to 4 carbon atoms are preferred.
  • X, X' or X" is an alkyl moiety, it is preferred that such have 1 to 12 carbon atoms and such moieties having 1 to 4 carbon atoms are especially preferred.
  • Electro-negative substituents which are particularly preferred are the halogens, i.e., fluorine, chlorine, bromine and iodine, N0 CF CN, as well as S-lower alkyl and -O-1ower alkyl; it is preferred that the alkyl moieties have 1 to 4 carbon atoms.
  • alkyl and lower alkyl comprises straight chain as well as branched chain alkyl moieties and also include those containing a double bond.
  • the salts of the N-trityl-imidazoles (I) are the pharmaceutically acceptable non-toxic acid salts.
  • suitable acids are the hydrohalic acids (hydrochloric being particularly preferred) phosphoric acid, monoand bifunctional carboxylic acids, such as acetic acid, propionic acid, maleic acid, succinic acid, fumaric acid, tartaric acid, citric acid, salicylic acid, sorbic acid, lactic acid and 1,5- naphthalene-disulphonic acid.
  • the hydrohalides, especially the hydrochlorides, lactates and salicylates are of particular value.
  • N-trityl-imidazoles have the formula:
  • X, X and X" are alkyl of 1 to- 12 carbon atoms or electro-negative substitutents and n, n and n" are 1 or 2.
  • substituent values are those where X" is fluorine, chlorine,
  • the compounds of the present invention can be prepared according to techniques per se known, such as by reacting silver salts or alkali metal salts, in particular the potassium salts of imidazoles of the Formula III with trityl halides of the Formula 1V:
  • the compounds of the present invention can also be prepared according to techniques per se by reacting imidazole derivatives of the Formula III with tritylcarbinols (cf. the reaction of the carbinol corresponding to the halide IV with secondary amines).
  • the imidazole is generally used in an excess of up to about 100%. If the process is carried out under pressure, molar amounts may be used. Furthermore, it may be expedient to carry out the elimination of water azeotropically in the presence of a high boiling inert organic solvent, such as xylene, chlorobenzenes and the like, at the boiling point of the solvent used. In the absence of solvents, the process is carried out at a temperature range of from about 140 C. to about 230 C. and preferably from about 170 C. to about 190 C.
  • dehydrating agents such as e.g. alkaline earth metal oxides (MgO, BaO, CaO) and of A1 0 approximately molar amounts being generally used, but possibly also in excess of up to about 2-3 moles.
  • dehydrating agents such as e.g. alkaline earth metal oxides (MgO, BaO, CaO) and of A1 0 approximately molar amounts being generally used, but possibly also in excess of up to about 2-3 moles.
  • the same compound can also be obtained, when finely powdered silver salt of imidazole is suspended with the equimolar amount of p chlorophenyl-diphenyl-methyl chloride in absolute benzene, the mixture is heated with stirring and with the exclusion of light at boiling temperature for about 3.hours, the precipitated silver chloride is subsequently filtered ofi and the residue remaining after removal of the solvent is recrystallised from benzene/ light petrol.
  • l-(tris-phenyl-methyl)-imidazole is produced from 1-tris-phenyl-methyl-carbinol and imidazole and l-(p-tolyl-diphenyl)-imidazole is produced from 1-p-tolyl-diphenylmethy1-carbinol and imidazole.
  • the other compounds (I, II) can also 'be obtained according to the above processes.
  • the conversion of the free compounds into the salts is likewise carried out in known manner.
  • the compounds (I, II) and their salts are effective against hyphomycetes as well as against yeasts, even in the case of oral administration. It is another advantage that the compounds according to the invention are well tolerated by warmblooded animals.
  • the compounds can be used as antimycotics, inter alia, in the form of an aqueous emulsion, suspension or solution which can be administered per os. It is also posible to use aqueous solutions of the new salts of the said compounds (I).
  • test medium was Milieu dpreuve according to Sabouraud.
  • Trich. asteroides 1 Trich. craterifor'me 10 Trich. equi-num (NL) 10 (4) Trich. equinum. woolly (H0eehst) 10 (5) Trich. eguirium. gran. (Hoechst) 10 Trich.tonsurans 2 (7) 7rich.verruc0su'm 4 (8) Trichgramtlosumu 2 (9) TTit'h.i7'Lt6TlIigil(ll 4 (10)"... Trich.megninii 0 1 (ll) Trich.mentagr0phyte 0 1 (12) Trich.
  • rubrum 2 (13)..- Microsp. audouiri (l4) Microsr). canis (NL) (15) Microsp. cam's (our isolation) 6) Microsp. duboisii (17) Microsp. fulvum- (18) Microsp. gallirzaa 9)- Microsp. felirzeum (20) Aspergillus niger-..
  • dermatomycoses caused by fungi of the species Trychophytes, Microsporium, Epidermophytes, Aspergillus, Candida albicans and other yeasts;
  • the compounds of the present invention are administered orally or parenterally as well as locally in the form of solutions, e.g., alcohol, preferably ethanol and isopropanol, buffer solutions, powders, tablets.
  • solutions e.g., alcohol, preferably ethanol and isopropanol, buffer solutions, powders, tablets.
  • the dosage range for humans is in the range of from about 20 to about mg./kg. and preferably from about 40 to about 60 mg./ kg. Administration is generally recommended at intervals of abp it 12 hours and such administration should be continued for from about 10 to about 60 days.
  • the compounds of the present invention can be used either as such or in combination with pharmaceutically acceptable carriers.
  • suitable forms for administration in combination with various inert carriers are tablets, capsules, powders, sprays, aqueous suspensions, injectable solutions, elixirs, syrups and the like.
  • Carriers of this type comprise solid extenders or fillers, a sterile aqueous medium as Well as various non-toxic organic solvents and the like.
  • the tablets and the like suitable for oral administration can be provided with an addition of saccharin or a similar additive.
  • the therapeutically active compound should be present in the total mixture at a concentration of about 0.5 to 90 percent by weight, i.e., in quantities which sutfice to attain the range of dosage mentioned above.
  • tablets may also contain additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch and the like, and binders such as polyvinyl-pyrrolidone, gelatin and the like. It is further possible to add lubricants such as magnesium stearate, sodium lauryl-sulphate and talc for producing tablets.
  • the active ingredient may be used together with various agents for improving the flavor, dyestuffs emulsifiers and/ or diluents, such as water, ethanol, propylene-glycol, glycerol and other compounds or combinations of this type.
  • aqueous solutions of the active ingredients in sesame or peanut oil or in aqueous propylene-glycol of N,N-dimethyl formamide, as well as sterile aqueous solutions if the compounds are Water-soluble.
  • aqueous solution should be buffered in the usual manner, if required, and the liquid diluent should previously be rendered isotonic by the addition of the necessary amount of salt or glucose.
  • aqueous solutions are particularly suitable for intraveneous, intramuscular and intraperitoneal injections.
  • a dosage of 40 mg./kg. administered at intervals of 12 hours result in a blood level of between and 11 'y/ml.
  • Up to 30 to 40% of the administered amount of the substance are excreted with the urine in active form.
  • the resorption quota amounts to more than 70% in the case of oral administration.
  • mice, rats, rabbits, dogs and cats lies between about 600 and 2200 mg. of the stated compounds/ kg. body weight in the case or oral administration.
  • the present invention also includes pharmaceutial compositions comprising at least one of the N-trityl-imidazoles or salts thereof in admixture with a solid or liquid diluent or carrier which may be any of the conventional diluents or carriers used in pharmaceutical compositions.
  • the present invention also includes unit dosage forms of medication which comprise at least one of the compounds of the present invention either alone or in admixture with a solidor liquid diluent or carrier.
  • the compounds of the present application may include a protective envelope or cover containing the active compound within.
  • Unit dosage form means that the composition is in the form of discrete portions, each containing a unit dose or a multiple or sub-multiple of the unit dose of the active ingredient which is the compound of the present invention.
  • Such portions may, for example, be in monolithic coherent form, such as tablets, suppositories, pills or dragees; in wrapped or concealed form, such as wrapped powders, cachets, sachets or capsules, in ampules such as in sterile solution; or in other forms known to the art.
  • An antifungal composition useful for administration to humans and animals which comprises a therapeutically eifective amount of a compound of the formula: II i Q Q wherein X" is CF or a pharmaceutically acceptable nontoxic salt thereof, sufiicient to be therapeutically effective against fungi pathogenic to humans and animals, in combination with a pharmaceutically acceptable non-toxic inert :liluent or carrier.
  • a method of treating fungal infections in humans and animals which comprises administering to a human or animal so afilicted an amount suflicient to be therapeutically effective against said infection of a compound of the formula:
  • X" is 0P or a pharmaceutically acceptable nontoxic salt thereof.

Abstract

N-TRITYL-IMIDAZOLES AND SALTS THEREOF OF THE FORMULA:

1-(((X)N-PHENYL)-C(-(1,4-PHENYLENE)-(X")N")(-(1,4-

PHENYLENE)-(X'')N'')-),2-R,4-R1,5-R2-IMIDAZOLE

WHEREIN

R, R1 AND R2 ARE HYDROGEN, LOWER ALKYL OR PHENYL, OR R1 AND R2 TOGETHER FORM AN ANELLATED BENZENE RING, X, X'' AND X" ARE ALKYL OF 1 TO 12 CARBON ATOMS OR AN ELECTRO-NEGATIVE MOIETY, AND N, N'' AND N" ARE AN INTEGER FROM 0 TO 2, OR PHARMACEUTICALLY ACCEPTABLE ACID SALTS THEREOF MAY BE PRODUCED BY REACTING A SILVER SALT OR ALKALI METAL SALT OF AN IMIDAZOLE OF THE FORMULA:

2-R,4-R1,5-R2-IMIDAZOLE

WITH A TRITYL HALIDE OF THE FORMULA:

(((X)N-PHENYL)-C(-HAL)(-(1,4-PHENYLENE)-(X")N")-),(X'')N''-

BENZENE

WHEREIN THE SUBSTITUENTS ARE AS ABOVE DEFINED AND HAL IS HALOGEN. THESE COMPOUNDS ARE USEFUL AS ANTIMYCOTICS.

Description

United States Patent Int. Cl. A61k 27/00 US. Cl. 424-273 4 Claims ABSTRACT OF THE DISCLOSURE N-trityl-imidazoles and salts thereof of the formula:
wherein R, R and R are hydrogen, lower alkyl or phenyl, or R and R together form an anellated benzene ring,
X, X and X" are alkyl of 1 to 12 carbon atoms or an electro-negative moiety, and
n, n and n are an integer from 0 to 2,
or pharmaceutically acceptable acid salts thereof may be produced by reacting a silver salt or alkali metal salt of an imidazole of the formula:
with a trityl halide of the formula:
wherein the substituents are as above defined and Hal is halogen. These compounds are useful as antimycotics.
This application is a division of our co-pending application Ser. No. 758,594 filed Sept. 9, 1968.
The present invention is concerned with N-tritylimidazoles and salts thereof and the production of such compounds. More particularly, the present invention is concerned with N-trityl-imidazoles and sales thereof of the formula:
la r: ,2 L. X n X'n' wherein R, R and R are hydrogen, lower alkyl or phenyl, or R and R together from an anellated benzene ring, X, X and X are alkyl of 1 to 12 carbon atoms or an electro-negative moiety, and n, n" and n" are an integer from 0 to 2,
or pharmaceutically acceptable acid salts thereof. When -R, R or R are alkyl moieties, those having 1 to 4 carbon atoms are preferred. When X, X' or X" is an alkyl moiety, it is preferred that such have 1 to 12 carbon atoms and such moieties having 1 to 4 carbon atoms are especially preferred. Electro-negative substituents which are particularly preferred are the halogens, i.e., fluorine, chlorine, bromine and iodine, N0 CF CN, as well as S-lower alkyl and -O-1ower alkyl; it is preferred that the alkyl moieties have 1 to 4 carbon atoms. The term alkyl and lower alkyl comprises straight chain as well as branched chain alkyl moieties and also include those containing a double bond.
The salts of the N-trityl-imidazoles (I) are the pharmaceutically acceptable non-toxic acid salts. Examples of suitable acids are the hydrohalic acids (hydrochloric being particularly preferred) phosphoric acid, monoand bifunctional carboxylic acids, such as acetic acid, propionic acid, maleic acid, succinic acid, fumaric acid, tartaric acid, citric acid, salicylic acid, sorbic acid, lactic acid and 1,5- naphthalene-disulphonic acid. The hydrohalides, especially the hydrochlorides, lactates and salicylates are of particular value.
In a particularly preferred embodiment of the present invention, the N-trityl-imidazoles have the formula:
wherein X, X and X" are alkyl of 1 to- 12 carbon atoms or electro-negative substitutents and n, n and n" are 1 or 2. With regard to Formula Ila, particularly preferred substituent values are those where X" is fluorine, chlorine,
3 bromine, iodine, N CF CN, SCH OCH and n" is 1.
The compounds of the present invention can be prepared according to techniques per se known, such as by reacting silver salts or alkali metal salts, in particular the potassium salts of imidazoles of the Formula III with trityl halides of the Formula 1V:
X/In (111) (IV) wherein R, R and R X, X and X and n, n and n" have the above meanings and Hal is chlorine, bromine or iodine, in an inert solvent such as benzene, toluene, hexane, cyclohexane or diethyl ether, at a temperature of from about 20 C. to about 110 C. [cf. Chem. Ber. 92, 92 (1959); 93, 570 (1960)]. I
The compounds of the present invention can also be prepared according to techniques per se by reacting imidazole derivatives of the Formula III with tritylcarbinols (cf. the reaction of the carbinol corresponding to the halide IV with secondary amines). In this case, the imidazole is generally used in an excess of up to about 100%. If the process is carried out under pressure, molar amounts may be used. Furthermore, it may be expedient to carry out the elimination of water azeotropically in the presence of a high boiling inert organic solvent, such as xylene, chlorobenzenes and the like, at the boiling point of the solvent used. In the absence of solvents, the process is carried out at a temperature range of from about 140 C. to about 230 C. and preferably from about 170 C. to about 190 C.
It may further be expedient to facilitate the elimination of water by working in the presence of dehydrating agents, such as e.g. alkaline earth metal oxides (MgO, BaO, CaO) and of A1 0 approximately molar amounts being generally used, but possibly also in excess of up to about 2-3 moles.
The following table gives the constants of some N-tritylimidazoles I, II) by way of example:
M.P.: C.
(a) l-(trisphenyl methyl)-imidazole 226-227 (b) l-(trisphenyl-methyl)-2-methyl-imidazole 225 (c) 1 (trisphenyl methyl) 2,4 dimethylimidazole 232 (d) 1 (trisphenyl methyl) 4,5 diphenylimidazole 228-230 (e) l (p chlorophenyl diphenyl methyl)- imidazole 140 (f) ,(p fluorophenyl diphenyl methyl)- imidazole 145 (g) 1-(p-tolyl-diphenyl-methyl)-imidazole 128 (h) l- (trisphenyl-methyl)-benzimidazole 180-181 (i) 1 o chlorophenyl diphenyl methyl)- imidazole 147-149 (J) 1 (m chlorophenyl diphenyl-methyl)- imidazole 1 14 (k) 1 (p bromophenyl diphenyl methyl)- imidazole 152 (l) 1 (o fluorophenyl diphenyl methyl)- imidazole l 85 (m) 1 (m fluorophenyl diphenyl-methyl)- imidazole 174 (n)l (p nitrophenyl diphenyl methyl)- imidazole 160-170 (o) 1 (m trifluoromethylphenyl-diphenyl- (y) 1 (o cyanophenyl diphenyl methyl) imidazole 149-151 EXAMPLE OF PREPARATION 1- [p-chlorophenyl-diphenyl-methyl] -imidazole (e) 7 K c m-o- -o1 I a s 1 mole p chlorophenyl diphenyl-methyl-carbinol is mixed with about 2' moles imidazole and the mixture is heated, without a solvent, at about 180 C. for 5 hours. After cooling, the reaction product is reprecipitated from xylene in order to remove the excess imidazole. After another reprecipitation from benzene light petrol, the pure 1 [p-chlorophenyl-diphenyl-methyl] -imidazole is obtained. M.P. -143 C.; yield 53% of theory.
The same compound can also be obtained, when finely powdered silver salt of imidazole is suspended with the equimolar amount of p chlorophenyl-diphenyl-methyl chloride in absolute benzene, the mixture is heated with stirring and with the exclusion of light at boiling temperature for about 3.hours, the precipitated silver chloride is subsequently filtered ofi and the residue remaining after removal of the solvent is recrystallised from benzene/ light petrol.
LBy analogous procedure, l-(tris-phenyl-methyl)-imidazole is produced from 1-tris-phenyl-methyl-carbinol and imidazole and l-(p-tolyl-diphenyl)-imidazole is produced from 1-p-tolyl-diphenylmethy1-carbinol and imidazole.
The other compounds (I, II) can also 'be obtained according to the above processes. The conversion of the free compounds into the salts is likewise carried out in known manner.
. Salts of trityl-imidazoles N triphenyl methyl-irnidazolium 1actate.31 g. N- trityl-imidazole are dissolved in 400 ml. carbon tetraand 10 g. (0.11 mole) dd-lactic acid are subsequently added. The residue remaining after distilling off the solvent is caused to crystallise by covering it with ether, the crystallisation product is washed with ether and dried. Yield 40 g. of a colourless crystalline powder of M.P. 170-180 C.
N triphenyl-methyl-imidazolium chloride.3l g. N- trithyl-imidazole are dissolved in 400 m1. carbon tetrachloride, and hydrogen chloride is subsequently passed into the solution at room temperature. The hydrochloride is precipitated after some time and filtered oil with suction. Colourless crystals of M.P. C. after recrystallisation from acetone/ether 1:1. Yield 33 g.
The following salts are obtained in an analogous manner:
1 (P chlorophenyl diphenyl-methyl)-imidazolium-chloride 128-30 1 (p chlorophenyl diphenyl-methyl)-imidazolium-lactate 90 1 (p chlorophenyl diphenyl-methyl)-imidzolium-salicylateoil. 1 (m chlorophenyl diphenyl-methyl)-imidazolium hydrochloride 153 1 (o chlorophenyl diphenyl-methyl)-imidazolium-chloride 159 1 (p fiuorophenyl diphenyl-methyl)-imidazolium-chloride 1 1 (p fiuorophenyl diphenyl-methyl)-imidazolium-lactate 95 1 ,(o fiuorophenyl diphenyl-methyl)-imidazolium-lactate 1 10 1 (m fiuorophenyl diphenyl-methyl)-imidazolium-lactate 120 1 (p fiuorophenyl diphenyl-methyD-imidazolium-salicylate 80 1 (p cyanophenyl diphenyl-methyl)- imidazolium-chloride 147 1 (o cyanophenyl diphenyl-methyl)-imidazolium-chloride 13 1 1 (p cyanophenyl diphenyl-methyl)-imidazolium-lactate 90 The previously known antimycotics are effective either only against yeasts, such as e.g. Amphotericin B, or only against hyphomycetes, such as e.g. Griseofulvin.
-In contrast thereto and surprisingly, the compounds (I, II) and their salts are effective against hyphomycetes as well as against yeasts, even in the case of oral administration. It is another advantage that the compounds according to the invention are well tolerated by warmblooded animals.
The compounds can be used as antimycotics, inter alia, in the form of an aqueous emulsion, suspension or solution which can be administered per os. It is also posible to use aqueous solutions of the new salts of the said compounds (I).
THERAPEUTIC EFFECT (1) In vitro-eifect against human-pathogenic fungi (a) Candida albicans:
compound (a) 40 'y/ml., compound (e) 4 'y/mL, compound (f) 4 /mL, compound (g) 4 'y/mL, compound (i) 4 'y/mL, compound (p) 4 'y/mL, fungistatic (b) Trichophyton mentagrophytes: 4-10 'y fungistatic microsp. fel. 4 'y The test medium was Milieu dpreuve according to Sabouraud.
The spectrum of activity and the intensity of activity (compound i) (in vitro) can be seen from the following table:
[Minimum inhibiting concentration as v/mL] Without With serum serum (1) Trich. asteroides 1 (2) Trich. craterifor'me 10 Trich. equi-num (NL) 10 (4) Trich. equinum. woolly (H0eehst) 10 (5) Trich. eguirium. gran. (Hoechst) 10 Trich.tonsurans 2 (7) 7rich.verruc0su'm 4 (8) Trichgramtlosumu 2 (9) TTit'h.i7'Lt6TlIigil(ll 4 (10)"... Trich.megninii 0 1 (ll) Trich.mentagr0phyte 0 1 (12) Trich. rubrum 2 (13)..- Microsp. audouiri (l4) Microsr). canis (NL) (15) Microsp. cam's (our isolation) 6) Microsp. duboisii (17) Microsp. fulvum- (18) Microsp. gallirzaa 9)- Microsp. felirzeum (20) Aspergillus niger-..
Pen. cornurie (22)..-" Mucor mucedo... (24) Carat. albicaris 1 Fungistase.
(2) Efiect in vivo (a) Experimental candidosis in white mice.-In the case of oral administration, curative elfects can be achieved with daily doses of 2-3 times 0.5-1 mg./mouse/day.
(b) Experimental trychophytia in mice caused by Trich. quinckeanrum-Development of the infection is prevented by daily doses of 1-2 times 1-2 mg./mouse orally.
(c) Experimental trychophytia in guinea pigs caused by Trish. mem.When 15-30 mg. are administered twice per os to guinea pigs weighing 400 grams, a reproducible effect on the course of the infection and rapid healing of the mycotic lesions is found.
Equally effective results are produced when other compounds Within the scope of (I) or salts of compounds within the scope of (I) and specifically salts of compounds (a), (e), (f), (g), (i) and (p) are used. Compounds which are unsubstituted in the imidazole ring may be substituted in one phenyl group by a halogen atom, preferably chlorine or fluorine in the 0-, mor p-position; such compounds and their salts with hydrochloric acid, lactic acid or salicylic acid are particularly useful. The following usages and dosage ranges are used for the compounds of the present invention:
(a) For use with humans:
(1) dermatomycoses, caused by fungi of the species Trychophytes, Microsporium, Epidermophytes, Aspergillus, Candida albicans and other yeasts;
(2) organomycoses caused by yeasts, mould fungi and dermatophytes;
(b) For veterinary use.-dermatomycoses and organomycoses caused by yeasts, mould fungi and dermatophytes.
The compounds of the present invention are administered orally or parenterally as well as locally in the form of solutions, e.g., alcohol, preferably ethanol and isopropanol, buffer solutions, powders, tablets.
The dosage range for humans is in the range of from about 20 to about mg./kg. and preferably from about 40 to about 60 mg./ kg. Administration is generally recommended at intervals of abp it 12 hours and such administration should be continued for from about 10 to about 60 days.
Nevertheless it may sometimes be necessary to digress from the aforesaid amounts, dependent on the method of administration or also on account of individual reactions to the medicine or on the type of its formulation and the moment in time or the intervals at which it is administered. In some cases, it may be suflicient to use less than the minimum amount stated above, whereas in other cases it may be necessary to go beyond the stated upper limit. If larger amounts are applied, it may be adgisable to distribute these over a day in several individual oses.
The compounds of the present invention can be used either as such or in combination with pharmaceutically acceptable carriers. Suitable forms for administration in combination with various inert carriers are tablets, capsules, powders, sprays, aqueous suspensions, injectable solutions, elixirs, syrups and the like. Carriers of this type comprise solid extenders or fillers, a sterile aqueous medium as Well as various non-toxic organic solvents and the like. Obviously, the tablets and the like suitable for oral administration can be provided with an addition of saccharin or a similar additive. In the aforesaid case, the therapeutically active compound should be present in the total mixture at a concentration of about 0.5 to 90 percent by weight, i.e., in quantities which sutfice to attain the range of dosage mentioned above.
In the case of oral administration, obviously, tablets may also contain additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch and the like, and binders such as polyvinyl-pyrrolidone, gelatin and the like. It is further possible to add lubricants such as magnesium stearate, sodium lauryl-sulphate and talc for producing tablets. In the case of aqueous suspensions and/or elixirs which are intended for oral administration; the active ingredient may be used together with various agents for improving the flavor, dyestuffs emulsifiers and/ or diluents, such as water, ethanol, propylene-glycol, glycerol and other compounds or combinations of this type.
In the case of parenteral administration, there may be used solutions of the active ingredients in sesame or peanut oil or in aqueous propylene-glycol of N,N-dimethyl formamide, as well as sterile aqueous solutions if the compounds are Water-soluble. Such aqueous solution should be buffered in the usual manner, if required, and the liquid diluent should previously be rendered isotonic by the addition of the necessary amount of salt or glucose. These aqueous solutions are particularly suitable for intraveneous, intramuscular and intraperitoneal injections.
In humans, a dosage of 40 mg./kg. administered at intervals of 12 hours result in a blood level of between and 11 'y/ml. The half-life period in human serum in vivo amouts to 6 hours on the average. Up to 30 to 40% of the administered amount of the substance are excreted with the urine in active form. The resorption quota amounts to more than 70% in the case of oral administration.
The LD for mice, rats, rabbits, dogs and cats lies between about 600 and 2200 mg. of the stated compounds/ kg. body weight in the case or oral administration.
The present invention also includes pharmaceutial compositions comprising at least one of the N-trityl-imidazoles or salts thereof in admixture with a solid or liquid diluent or carrier which may be any of the conventional diluents or carriers used in pharmaceutical compositions.
The present invention also includes unit dosage forms of medication which comprise at least one of the compounds of the present invention either alone or in admixture with a solidor liquid diluent or carrier. The compounds of the present application may include a protective envelope or cover containing the active compound within. Unit dosage form means that the composition is in the form of discrete portions, each containing a unit dose or a multiple or sub-multiple of the unit dose of the active ingredient which is the compound of the present invention. Such portions may, for example, be in monolithic coherent form, such as tablets, suppositories, pills or dragees; in wrapped or concealed form, such as wrapped powders, cachets, sachets or capsules, in ampules such as in sterile solution; or in other forms known to the art.
What is claimed is:
1. An antifungal composition useful for administration to humans and animals, which comprises a therapeutically eifective amount of a compound of the formula: II i Q Q wherein X" is CF or a pharmaceutically acceptable nontoxic salt thereof, sufiicient to be therapeutically effective against fungi pathogenic to humans and animals, in combination with a pharmaceutically acceptable non-toxic inert :liluent or carrier.
2. An antifungal composition according to claim 1, wherein the compound is l- (m-trifluoromethyl-phenyl-diphenylmethyl)-imidazole.
3. A method of treating fungal infections in humans and animals, which comprises administering to a human or animal so afilicted an amount suflicient to be therapeutically effective against said infection of a compound of the formula:
wherein X" is 0P or a pharmaceutically acceptable nontoxic salt thereof.
4. A method according to claim 3, wherein the compound is 1 (m-trifiuoromethyl-phenyl-diphenyl-methyl)- imidazole.
References Cited UNITED STATES PATENTS 3,321,366 5/1967 Mussell et al 424--273 JEROME D. GOLDBERG, Primary Examiner
US36425A 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections Expired - Lifetime US3655899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEF0053504 1967-09-15
LU57488 1968-12-06
US21852472A 1972-01-17 1972-01-17

Publications (1)

Publication Number Publication Date
US3655899A true US3655899A (en) 1972-04-11

Family

ID=27210542

Family Applications (16)

Application Number Title Priority Date Filing Date
US758594A Expired - Lifetime US3660577A (en) 1967-09-15 1968-09-09 N-trityl-imidazoles as antifungal agents
US13797A Expired - Lifetime US3705172A (en) 1967-09-15 1970-02-24 N-trityl-imidazoles
US36425A Expired - Lifetime US3655899A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US36424A Expired - Lifetime US3658956A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US36426A Expired - Lifetime US3655900A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US36396A Expired - Lifetime US3660576A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US36395A Expired - Lifetime US3657445A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US36394A Expired - Lifetime US3657442A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US00126277A Expired - Lifetime US3720770A (en) 1967-09-15 1971-03-19 1-(p-chloro-m-nitrophenyl-diphenylmethyl)-imidazole as an antifungal agent
US00161274A Expired - Lifetime US3839573A (en) 1967-09-15 1971-07-09 Antifungal compositions and methods of treatment employing n-trityl imidazoles
US00218525A Expired - Lifetime US3711500A (en) 1967-09-15 1972-01-17 N-trityl-imidazoles
US00218519A Expired - Lifetime US3767668A (en) 1967-09-15 1972-01-17 Process for the production of n-trityl-imidazoles
US00218526A Expired - Lifetime US3711501A (en) 1967-09-15 1972-01-17 N-trityl-imidazoles
US00218521A Expired - Lifetime US3711498A (en) 1967-09-15 1972-01-17 N-trityl-imidazoles
US00218524A Expired - Lifetime US3717657A (en) 1967-09-15 1972-01-17 N-trityl-imidazoles
US00218523A Expired - Lifetime US3711499A (en) 1967-09-15 1972-01-17 N-trityl-imidazoles

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US758594A Expired - Lifetime US3660577A (en) 1967-09-15 1968-09-09 N-trityl-imidazoles as antifungal agents
US13797A Expired - Lifetime US3705172A (en) 1967-09-15 1970-02-24 N-trityl-imidazoles

Family Applications After (13)

Application Number Title Priority Date Filing Date
US36424A Expired - Lifetime US3658956A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US36426A Expired - Lifetime US3655900A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US36396A Expired - Lifetime US3660576A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US36395A Expired - Lifetime US3657445A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US36394A Expired - Lifetime US3657442A (en) 1967-09-15 1970-05-11 N-trityl-imidazoles for treating fungal infections
US00126277A Expired - Lifetime US3720770A (en) 1967-09-15 1971-03-19 1-(p-chloro-m-nitrophenyl-diphenylmethyl)-imidazole as an antifungal agent
US00161274A Expired - Lifetime US3839573A (en) 1967-09-15 1971-07-09 Antifungal compositions and methods of treatment employing n-trityl imidazoles
US00218525A Expired - Lifetime US3711500A (en) 1967-09-15 1972-01-17 N-trityl-imidazoles
US00218519A Expired - Lifetime US3767668A (en) 1967-09-15 1972-01-17 Process for the production of n-trityl-imidazoles
US00218526A Expired - Lifetime US3711501A (en) 1967-09-15 1972-01-17 N-trityl-imidazoles
US00218521A Expired - Lifetime US3711498A (en) 1967-09-15 1972-01-17 N-trityl-imidazoles
US00218524A Expired - Lifetime US3717657A (en) 1967-09-15 1972-01-17 N-trityl-imidazoles
US00218523A Expired - Lifetime US3711499A (en) 1967-09-15 1972-01-17 N-trityl-imidazoles

Country Status (5)

Country Link
US (16) US3660577A (en)
BE (1) BE720801A (en)
FR (2) FR1597530A (en)
GB (1) GB1170188A (en)
LU (1) LU57488A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG9984A (en) * 1968-07-20 1976-08-31 Bayer Ag N-diaryl-pyridyl-methyl-imidazoles and their salts
CH531518A (en) * 1968-11-29 1972-12-15 Bayer Ag Process for the preparation of N-substituted imidazoles and their salts
DE2009020C3 (en) * 1970-02-26 1979-09-13 Bayer Ag, 5090 Leverkusen Process for the preparation of N- (l, l, l-trisubstituted) -methylazoles
US3980780A (en) * 1970-03-23 1976-09-14 Bayer Aktiengesellschaft N-Methyl-imidazole derivatives for treating mycotic infections
US3764609A (en) * 1970-06-22 1973-10-09 Koninklijke Pharma Fab Nv 1 (dibenzo {8 4,d{9 {0 cyclohepten-5-yl), 1-(dibenzo {8 a,d{9 {0 cycloheptan-5-yl) and 1-(dibenzo {8 a,d{9 {0 cyclooctanyl)imidazoles
DE2037610A1 (en) * 1970-07-29 1972-02-03 Bayer Ag New alpha-substituted benzyl-azoles, processes for their production and their use as pharmaceuticals
DE2213863C3 (en) * 1972-03-22 1982-05-13 Bayer Ag, 5090 Leverkusen Disubstituted triphenylmethylimidazoles, processes for their preparation and pharmaceuticals containing them
US4117142A (en) * 1972-03-22 1978-09-26 Bayer Aktiengesellschaft Disubstituted triphenylmethylmidazoles for treating mycotic infections
DE2314985A1 (en) * 1973-03-26 1974-10-17 Hoechst Ag 1- (IMIDAZOL-1-YL) -ISOCHINOLINES AND THE PROCESS FOR THEIR MANUFACTURE
JPS6048486B2 (en) * 1976-01-01 1985-10-28 木場 常義 antirheumatic agent
FR2387658A1 (en) * 1977-03-25 1978-11-17 Ciba Geigy Ag PROCEDURE FOR FIGHTING MICROORGANISMS
US4267169A (en) * 1978-07-22 1981-05-12 Toko Yakuhin Kogyo Kabushiki Kaisha Novel preparation of clotrimazole
US4216333A (en) * 1978-10-30 1980-08-05 Sumitomo Chemical Company, Limited Process for preparing N-tritylimidazole compounds
US4439441A (en) * 1979-01-11 1984-03-27 Syntex (U.S.A.) Inc. Contraceptive compositions and methods employing 1-substituted imidazole derivatives
JPS5692887A (en) * 1979-12-05 1981-07-27 Sumitomo Chem Co Ltd N-substituted imidazole derivative
JPS58150566A (en) * 1982-03-03 1983-09-07 Yoshitomi Pharmaceut Ind Ltd Novel imidazole derivative
US4755526A (en) * 1984-06-18 1988-07-05 Eli Lilly And Company Method of inhibiting aromatase
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4937250A (en) * 1988-03-07 1990-06-26 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
DE3865675D1 (en) * 1988-07-28 1991-11-21 Uriach & Cia Sa J 1 - ((2-FLUOROPHENYL) (4-FLUOROPHENYL) PHENYLMETHYL) -1H-IMIDAZOLE.
US5177099A (en) * 1989-04-10 1993-01-05 Sociedad Espanola De Especialidades Farmaco-Terapeuticas S.A. Dichloro-substituted imidazole derivatives as antifungal agents
US5100908A (en) * 1990-03-06 1992-03-31 Ss Pharmaceutical Co., Ltd. Antimycotic external imidazole preparations
AU4399793A (en) * 1992-06-08 1994-01-04 Schering-Plough Healthcare Products, Inc. Stable imidazole anti-fungal powder compositions
US6177427B1 (en) * 1994-06-28 2001-01-23 Alcon Laboratories, Inc. Treatment of glaucoma and ocular hypertension
AU1224599A (en) * 1997-11-14 1999-06-07 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
US6103733A (en) * 1998-09-09 2000-08-15 Bachmann; Kenneth A. Method for increasing HDL cholesterol levels using heteroaromatic phenylmethanes
US6080744A (en) * 1999-02-10 2000-06-27 Ayon-Covarrubias; Blas Topical antifungal treatment
US6450515B1 (en) * 2000-10-10 2002-09-17 James F. Guth Clip-on wheels for pallets or other structures with runners
US20060211632A1 (en) * 2005-03-17 2006-09-21 Bachmann Kenneth A PXR agonists for cardiovascular disease
EP1958613A1 (en) * 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin
CL2008003553A1 (en) * 2007-12-05 2009-11-27 Grindeks Jsc Process to prepare atipamezole or 5- (2-ethyl-2,3-dihydro-1h-inden-2-yl) -1h-imidazole hydrochloride: and the intermediate compounds considered in the process
BRPI0904249B1 (en) 2009-08-28 2018-03-06 Biolab Sanus Farmacêutica Ltda. BENZYL ARALQUIL ETHER COMPOUNDS, PREPARATION PROCESS FOR THEM, USE OF SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITION
UA118087C2 (en) 2009-10-01 2018-11-26 Адер Фармасьютікалз, Інк. CORTICOSTEROID COMPOSITION, ORALIZED
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
JP6723698B2 (en) * 2015-07-23 2020-07-15 東京応化工業株式会社 Fine particle-containing composition
US20170112824A1 (en) * 2015-10-23 2017-04-27 Wright State University Combination therapies for the treatment of fungal infections
TWI777515B (en) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 Methods of treating eosinophilic esophagitis
EP3558304A2 (en) 2016-12-23 2019-10-30 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321366A (en) * 1965-11-15 1967-05-23 Dow Chemical Co Fungicidal methods and compositions

Also Published As

Publication number Publication date
US3657445A (en) 1972-04-18
LU57488A1 (en) 1969-03-13
US3767668A (en) 1973-10-23
FR8112M (en) 1970-07-27
US3660576A (en) 1972-05-02
US3711498A (en) 1973-01-16
US3839573A (en) 1974-10-01
US3660577A (en) 1972-05-02
US3655900A (en) 1972-04-11
DE1617481A1 (en) 1971-04-08
US3711499A (en) 1973-01-16
BE720801A (en) 1969-03-13
US3658956A (en) 1972-04-25
US3711501A (en) 1973-01-16
DE1617481B2 (en) 1975-07-24
US3657442A (en) 1972-04-18
US3711500A (en) 1973-01-16
US3720770A (en) 1973-03-13
FR1597530A (en) 1970-06-29
US3705172A (en) 1972-12-05
US3717657A (en) 1973-02-20
GB1170188A (en) 1969-11-12

Similar Documents

Publication Publication Date Title
US3655899A (en) N-trityl-imidazoles for treating fungal infections
US3755349A (en) Alpha-substituted benzyl-imidazoles
US3796704A (en) Phenyl-imidazolylalkanyl derivatives
IL33918A (en) Substituted n-benzylimidazoles,their production and pharmaceutical compositions containing them
US4171365A (en) Antiviral aryloxyalkylpyrazoles
US3870726A (en) Derivatives of 3-azolylpropyne and processes for their preparation and use
US3881014A (en) N-tritylimidazoles for treating fungal infections
US4234725A (en) 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US3711487A (en) Certain alpha,alpha-disubstituted benzylimidazoles and salts
US4261928A (en) 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4232161A (en) 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US3821394A (en) Antimycotic composition and method employing a substituted benzyl-azoles
US3778447A (en) N-(substituted)fluorene-,dibenzocycloheptane-and dibenzocycloheptene-imidazoles
US3892764A (en) Phenyl-imidazolyl-alkanyl derivatives, their production and use
US4209526A (en) Antiviral arylenedioxyalkyl substituted pyrazoles
US3872095A (en) N-trityl-imidazoles and their production
US3787415A (en) N-methyl-imidazole derivatives and their production
JPS6030290B2 (en) Pharmaceutical compositions and uses
US3928348A (en) N-methyl-imidazole derivatives and their production
US4052409A (en) Disubstituted triphenylmethylimidazoles
IL43298A (en) Omega,omega-diphenyl-omega-imidazolyl-1-acetic acid amides,their production and pharmaceutical compositions containing them
US3826837A (en) 9-azolyl-(1)-fluorene-9-carboxylic acid derivatives as an anti-mycotic agent
US3629273A (en) N-diaryl-pyridyl-methyl-imidazoles salts thereof
IL36487A (en) Derivatives of phenyl-imidazolyl (or 1,2,4-triazolyl) fatty acids,their production and their use as medicines
US3737531A (en) N-diaryl-pyridyl-methyl-imidazoles,salts thereof as antifungal agents